Literature DB >> 22084441

Rat and mouse CD94 associate directly with the activating transmembrane adaptor proteins DAP12 and DAP10 and activate NK cell cytotoxicity.

Per C Saether1, Sigurd E Hoelsbrekken, Sigbjørn Fossum, Erik Dissen.   

Abstract

Signaling by the CD94/NKG2 heterodimeric NK cell receptor family has been well characterized in the human but has remained unclear in the mouse and rat. In the human, the activating receptor CD94/NKG2C associates with DAP12 by an ionic bond between oppositely charged residues within the transmembrane regions of NKG2C and DAP12. The lysine residue responsible for DAP12 association is absent in rat and mouse NKG2C and -E, raising questions about signaling mechanisms in these species. As a possible substitute, rat and mouse NKG2C and -E contain an arginine residue in the transition between the transmembrane and stalk regions. In this article, we demonstrate that, similar to their human orthologs, NKG2A inhibits, whereas NKG2C activates, rat NK cells. Redirected lysis assays using NK cells transfected with a mutated NKG2C construct indicated that the activating function of CD94/NKG2C did not depend on the transmembrane/stalk region arginine residue. Flow cytometry and biochemical analysis demonstrated that both DAP12 and DAP10 can associate with rat CD94/NKG2C. Surprisingly, DAP12 and DAP10 did not associate with NKG2C but instead with CD94. These associations depended on a transmembrane lysine residue in CD94 that is unique to rodents. Thus, in the mouse and rat, the ability to bind activating adaptor proteins has been transferred from NKG2C/E to the CD94 chain as a result of mutation events in both chains. Remarkable from a phylogenetic perspective, this sheds new light on the evolution and function of the CD94/NKG2 receptor family.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084441     DOI: 10.4049/jimmunol.1102345

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.

Authors:  Aaron S Rapaport; Jill Schriewer; Susan Gilfillan; Ed Hembrador; Ryan Crump; Beatrice F Plougastel; Yaming Wang; Gaelle Le Friec; Jian Gao; Marina Cella; Hanspeter Pircher; Wayne M Yokoyama; R Mark L Buller; Marco Colonna
Journal:  Immunity       Date:  2015-12-08       Impact factor: 31.745

2.  Evidence of functional Cd94 polymorphism in a free-living house mouse population.

Authors:  Linn E Knutsen; Erik Dissen; Per C Saether; Elisabeth Gyllensten Bjørnsen; Jaroslav Piálek; Anne K Storset; Preben Boysen
Journal:  Immunogenetics       Date:  2018-12-10       Impact factor: 2.846

3.  Simian Immunodeficiency Virus Infection Modulates CD94+ (KLRD1+) NK Cells in Rhesus Macaques.

Authors:  Daniel R Ram; Olivier Lucar; Brady Hueber; R Keith Reeves
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

4.  NKG2C/E Marks the Unique Cytotoxic CD4 T Cell Subset, ThCTL, Generated by Influenza Infection.

Authors:  Nikki B Marshall; Allen M Vong; Priyadharshini Devarajan; Matthew D Brauner; Yi Kuang; Ribhu Nayar; Elizabeth A Schutten; Catherine H Castonguay; Leslie J Berg; Stephen L Nutt; Susan L Swain
Journal:  J Immunol       Date:  2016-12-28       Impact factor: 5.422

5.  High diversification of CD94 by alternative splicing in New World primates.

Authors:  John A Galindo; Luis F Cadavid
Journal:  Immunogenetics       Date:  2013-01-31       Impact factor: 2.846

Review 6.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

7.  Viral infection modulates Qa-1b in infected and bystander cells to properly direct NK cell killing.

Authors:  Maria Ferez; Cory J Knudson; Avital Lev; Eric B Wong; Pedro Alves-Peixoto; Lingjuan Tang; Colby Stotesbury; Luis J Sigal
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.